Among patients undergoing clinically indicated left atrial appendage closure (LAAC) and in whom LAA anatomy was deemed suitable for either the Amulet or Watchman FLX device, there was no difference in device-related and clinical outcomes at 13 months, according to a prespecified analysis of the SWISS-APERO trial.